Stoke Therapeutics (STOK) Stock Forecast & Price Target

Compare

466 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

STOK Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Stoke

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

STOK Stock 12 Month Forecast

Average Price Target

$35.25

▲(4.66% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $35.25 with a high forecast of $50.00 and a low forecast of $25.00. The average price target represents a 4.66% change from the last price of $33.68.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","28":"$28","51":"$51","16.5":"$16.5","39.5":"$39.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$35.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,16.5,28,39.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.74,33.144615384615385,34.54923076923077,35.95384615384615,37.35846153846154,38.76307692307692,40.167692307692306,41.57230769230769,42.97692307692308,44.38153846153846,45.786153846153844,47.190769230769234,48.59538461538462,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.74,32.01,32.28,32.55,32.82,33.089999999999996,33.36,33.63,33.9,34.17,34.44,34.71,34.98,{"y":35.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.74,31.22153846153846,30.70307692307692,30.184615384615384,29.666153846153847,29.147692307692306,28.62923076923077,28.11076923076923,27.592307692307692,27.073846153846155,26.555384615384614,26.036923076923078,25.518461538461537,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.07,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.85,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.91,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.09,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.74,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$35.25

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sumant Kulkarni

Canaccord Genuity

$28→$36

Buy

6.89%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK), Fate Therapeutics (NASDAQ: FATE) and Alto Neuroscience, Inc. (NYSE: ANRO)Nice tango with FDA on faster path or not, we like opportunity on zorevunersen for Dravet syndrome; PT to $36, reiterate BUY

Keay Nakae

Chardan Capital

$35

Buy

3.92%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK) and IDEAYA Biosciences (NASDAQ: IDYA)

Ananda Ghosh

H.C. Wainwright

$35→$50

Buy

48.46%

Upside

Reiterated

12/15/25

Stoke Therapeutics price target raised to $50 from $35 at H.C. WainwrightStoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright

Andrew Tsai

Jefferies

$30

Buy

-10.93%

Downside

Reiterated

11/24/25

Jefferies Sticks to Their Buy Rating for Stoke Therapeutics (STOK)

Laura Chico

Wedbush

$32

Buy

-4.99%

Downside

Reiterated

11/17/25

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK) and Masimo (NASDAQ: MASI)

Joseph Stringer

Needham

$35

Buy

3.92%

Upside

Reiterated

11/05/25

Positive Outlook for Stoke Therapeutics: Buy Rating Reinforced by Phase 3 Trial Progress and Regulatory Engagement

Yaron Werber

TD Cowen

Buy

―

Reiterated

11/04/25

Promising Potential and Strong Financial Position Drive Buy Rating for Stoke Therapeutics

Thomas Shrader

BTIG

$39

Buy

15.80%

Upside

Reiterated

11/04/25

Stoke Therapeutics: Promising Outlook with Breakthrough Therapy Designation and Strong Financial Position

Jessica Fye

J.P. Morgan

$15→$25

Hold

-25.77%

Downside

Reiterated

11/03/25

Stoke Therapeutics price target raised to $25 from $15 at JPMorganStoke Therapeutics price target raised to $25 from $15 at JPMorgan

Marc Goodman

Leerink Partners

$18→$30

Buy

-10.93%

Downside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), Stoke Therapeutics (NASDAQ: STOK) and Certara (NASDAQ: CERT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sumant Kulkarni

Canaccord Genuity

$28→$36

Buy

6.89%

Upside

Reiterated

01/05/26

Keay Nakae

Chardan Capital

$35

Buy

3.92%

Upside

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK) and IDEAYA Biosciences (NASDAQ: IDYA)

Ananda Ghosh

H.C. Wainwright

$35→$50

Buy

48.46%

Upside

Reiterated

12/15/25

Stoke Therapeutics price target raised to $50 from $35 at H.C. WainwrightStoke Therapeutics price target raised to $50 from $35 at H.C. Wainwright

Andrew Tsai

Jefferies

$30

Buy

-10.93%

Downside

Reiterated

11/24/25

Jefferies Sticks to Their Buy Rating for Stoke Therapeutics (STOK)

Laura Chico

Wedbush

$32

Buy

-4.99%

Downside

Reiterated

11/17/25

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK) and Masimo (NASDAQ: MASI)

Joseph Stringer

Needham

$35

Buy

3.92%

Upside

Reiterated

11/05/25

Positive Outlook for Stoke Therapeutics: Buy Rating Reinforced by Phase 3 Trial Progress and Regulatory Engagement

Yaron Werber

TD Cowen

Buy

―

Reiterated

11/04/25

Promising Potential and Strong Financial Position Drive Buy Rating for Stoke Therapeutics

Thomas Shrader

BTIG

$39

Buy

15.80%

Upside

Reiterated

11/04/25

Stoke Therapeutics: Promising Outlook with Breakthrough Therapy Designation and Strong Financial Position

Jessica Fye

J.P. Morgan

$15→$25

Hold

-25.77%

Downside

Reiterated

11/03/25

Stoke Therapeutics price target raised to $25 from $15 at JPMorganStoke Therapeutics price target raised to $25 from $15 at JPMorgan

Marc Goodman

Leerink Partners

$18→$30

Buy

-10.93%

Downside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: AnaptysBio (NASDAQ: ANAB), Stoke Therapeutics (NASDAQ: STOK) and Certara (NASDAQ: CERT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Stoke Therapeutics

1 Month

xxx

Success Rate

20/37 ratings generated profit

Average Return

+1.40%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.05% of your transactions generating a profit, with an average return of +1.40% per trade.

3 Months

xxx

Success Rate

9/15 ratings generated profit

Average Return

+9.47%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +9.47% per trade.

1 Year

Thomas ShraderBTIG

Success Rate

17/25 ratings generated profit

Average Return

+65.34%

reiterated a buy rating 2 months ago

Copying Thomas Shrader's trades and holding each position for 1 Year would result in 68.00% of your transactions generating a profit, with an average return of +65.34% per trade.

2 Years

xxx

Success Rate

14/15 ratings generated profit

Average Return

+145.15%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 93.33% of your transactions generating a profit, with an average return of +145.15% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

STOK Analyst Recommendation Trends

Rating

Aug 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, STOK has received 12 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. STOK average Analyst price target in the past 3 months is 35.25.

Each month's total comprises the sum of three months' worth of ratings.

STOK Financial Forecast

STOK Earnings Forecast

Next quarter’s earnings estimate for STOK is -$0.72 with a range of -$0.84 to -$0.55. The previous quarter’s EPS was -$0.65. STOK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year STOK has Performed in-line its overall industry.

STOK Sales Forecast

Next quarter’s sales forecast for STOK is $5.40M with a range of $1.50M to $13.00M. The previous quarter’s sales results were $10.63M. STOK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year STOK has Performed in-line its overall industry.

STOK Stock Forecast FAQ

What is STOK’s average 12-month price target, according to analysts?

Based on analyst ratings, Stoke Therapeutics Inc’s 12-month average price target is 35.25.

What is STOK’s upside potential, based on the analysts’ average price target?

Stoke Therapeutics Inc has 4.66% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is STOK a Buy, Sell or Hold?

Stoke Therapeutics Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Stoke Therapeutics Inc’s price target?

The average price target for Stoke Therapeutics Inc is 35.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $25.00. The average price target represents 4.66% Increase from the current price of $33.68.

What do analysts say about Stoke Therapeutics Inc?

Stoke Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of STOK?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Stoke Therapeutics (STOK) Stock Forecast & Price Target

STOK Analyst Ratings

STOK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Stoke Therapeutics

STOK Analyst Recommendation Trends

STOK Financial Forecast

STOK Earnings Forecast

STOK Sales Forecast

STOK Stock Forecast FAQ

Detailed List of Analyst Forecasts